this must be archive.php

MDS UK has new recruits!

Exciting staff news at MDS UK

After a busy recruiting period, we have filled our advertised positions and are delighted to say we have 3 new people who’ve joined our team!

Continue reading…


Would you like to see an MDS Specialist?

The UK MDS Forum is a UK specialist group of haematologist, which works extensively with other MDS experts worldwide. Its haematologists are MDS experts and have extensive experience treating MDS patients. They can work with your local haematologist to offer you the best possible care and advice.

Under NHS rules, you are free to seek a referral to the hospital of your choice.

To get a referral, please just ask your GP or your haematologist to refer you. You will receive an appointment in the post as soon as possible.

If you'd like more information please contact us info@mdspatientsupport.org.uk or call 020 7733 7558

MDS Patient Support

How can you access this service?

MDS is a rarer disease, and often requires an MDS expert to evaluate the exact sub-type of MDS, or explore and discuss additional treatment options, including clinical trials.

Your haematologist, or GP, needs to refer via the traditional referral system.

An appointment will be arranged after receipt of a formal referral from either the GP or local haematologist, which should contain as much detail as possible, specifically results of bone marrow tests and details of treatment, if relevant.

Note:
The online clinical consultations with Prof Bowen are no longer available unfortunately.
The patients who took advantage of this service were extremely satisfied, but the general uptake amongst patients was not as high as initially hoped.
Should such a service be made available again, via Leeds, or elsewhere – we will of course let everyone know.

Would you like to share your questions about MDS?
We can help you - Contact us
Send an email to info@mdspatientsupport.org.uk
or call 020 7733 7558


Volunteer With Us

Enthusiastic volunteers needed!

Enthusiastic volunteers needed!

We are always looking for enthusiastic new volunteers to help with various aspects of our expanding patient services

  • Have you or your loved one benefited from helpful information, support, or other services from MDS UK?
  • Would you like to be part of a team of enthusiastic volunteer MDS Ambassadors to help maintain our vital services to all those affected by MDS and CMML?
  • Do you have a little spare time and looking for something fulfilling?
  • Do you have skills and experience from previous paid or voluntary work?
  • Could you help make a difference to MDS UK?

If you have answered “Yes” to these questions and are interested in knowing more, please have a look at our MDS UK Ambassador leaflet, for more details on the roles, or visit our Ambassadors Page.

Find out how to become an MDS UK Ambassador

As an MDS Ambassador you could help us take our aims forward to the next level!
An Ambassador could be somebody who has MDS, or a friend or family member of somebody with MDS.

Download PDF

Interested in finding out more? Please send us details of your skills and experience, why you would like to volunteer, and a little about yourself.  We can then arrange an informal chat about what is involved in becoming an MDS UK Ambassador.

Email Us

Christine Dugmore, Volunteer Coordinator

essexgroup@mdspatientsupport.org.uk

Give us a call!

Phone: 07957 598822 / 01702 478244


Take part in an NHS consultation on new standards to diagnose cancers earlier

The NHS launches a consultation on proposed new standards that will help diagnose more cancers earlier and save more lives

Developed with clinical leaders, the proposals – supported by NHS staff as well as patient groups and cancer charities – aim to simplify and update cancer standards, based on the recommendations of the Independent Cancer Taskforce.

Patients, clinicians and the public are asked to share their views on the proposed standards, with a report setting out the changes published today.

Cancer currently has a complex set of nine separate performance standards, with different targets covering different routes into the system, for example, screening or a GP referral.

The new plan proposes ensuring patients have the same opportunity for faster diagnosis and treatment, including:

  • The 28-day faster diagnosis standard, which would see patients who have been urgently referred, have breast symptoms, or have been picked up through screening, have cancer ruled out or receive a diagnosis within 28 days.
  • A 62-day referral to treatment standard, meaning patients who receive a cancer diagnosis will start treatment within nine weeks from the date of referral.
  • A 31-day decision to treat to treatment standard, so that cancer patients receive their first treatment within a month of a decision to treat following diagnosis.

These new standards aim to make diagnosis and treatment timelines easier to understand for people with suspected cancer and their families, while also helping to diagnose cancers earlier and save more lives.

Before the faster diagnosis standard was introduced, access standards for cancer have remained unchanged since 2009. The current two week wait target sets no expectation of when patients should receive test results or actually get a confirmed diagnosis.

Cancer care has been prioritised throughout the pandemic with latest data showing the number of people getting checked for cancer increased by over half a million (512,110) in one year between December 2020 and December 2021.

In December alone, there were over 215,000 urgent referrals for cancer and more than nine out of 10 people started treatment within one month.

Dame Cally Palmer, NHS National Director for Cancer said: “Access standards have been key to improving timeliness of treatment for people with cancer since they were first introduced in 2000.

“As we see advances in diagnosis and treatments for cancer, it is only right that these standards are modernised – so that we can ensure patients are diagnosed more quickly and are given the treatment they need as soon as possible, helping us save even more lives.

“These proposed changes are an important part of improving cancer care and so from today, the NHS will be inviting views from patients, staff and the public”.

Professor Peter Johnson, National Clinical Director for Cancer for NHS England, said: “We know that people having tests for possible cancer want to know the results quickly, and updating the standards to reflect this will help us to make sure we are able to deliver the best possible care.

“We are encouraging colleagues in NHS cancer services to share their views on the consultation to ensure we have standards that are better for people with cancer”.

Health and Social Care Secretary, Sajid Javid said: “As part of our 10-Year Cancer Plan, we want to offer patients the best possible care and treatment.

“These proposals will help us speed up diagnosis times and treatment, and save more lives.

“The NHS wants to hear from as many people as possible – and is seeking advice from patients, staff and the public. Please, make your voices heard”.

Under the new proposals, the NHS would focus on the time from referral to people finding out their results within a maximum of 28 days. This faster diagnosis standard has a clearer focus on measuring and incentivising early diagnosis, rather than just time to first be seen.

Areas where the new standards have been tested have shown that performance against the 62-day referral to treatment standard was significantly higher (74.9%) than the control group (71.7%) when using the new measures.

Proposals are in addition to the target announced in the elective recovery plan, published last month, which outlined the NHS aim to return the number of people waiting more than 62 days from an urgent referral back to pre-pandemic levels by March 2023.

Catherine Harper-Wynne, Chair of the Breast Cancer Faster Diagnosis Group, said: “The proposed update in standards provides a better reflection of our current clinical approach and allows for greater flexibility to offer patients the most efficient route to diagnosis, allowing us to start treatment as quickly as possible. For breast cancer patients, there is evidence, from the pilot already completed, that a higher proportion of patients had cancer ruled out within 28 days”.

Jane Lyons, CEO of charity Cancer52, said: “People with rare and less common cancers often have vague symptoms and it can take longer for their cancer to be diagnosed. So a commitment to a diagnosis in 28 days for all cancers, including those that are more challenging to diagnose, is a good step forward. Earlier diagnosis can mean more people start treatment sooner and more lives will be saved, and we support work to help the NHS meet its ambitions to diagnose more cancers faster and earlier”.

Patients have told the NHS that the focus on achieving a rapid diagnosis or ruling out of cancer is the right one, and is more meaningful to patients than the timing of a first appointment.


3rd & 4th doses COVID-19 vaccination for MDS patients

Coronavirus (COVID-19) vaccine for people with a severely weakened immune system - Updated March 9th, 2022

A 3rd dose and booster dose (4th dose) of the coronavirus (COVID-19) vaccine is being offered to people aged 12 and over who had a severely weakened immune system when they had their first 2 doses.

This includes patients who had or have a blood cancer such as MDS or CMML and patients who had a bone marrow transplant.

If you're booking a 3rd dose all of these must apply:

  • you’ve received a letter from your GP or hospital specialist inviting you to book a 3rd dose
  • you’re aged 16 years old or over
  • it’s been 26 days since your previous dose - you'll be shown appointments from 8 weeks (56 days) after your 2nd dose
  • You’ll need to bring the letter with you to your appointment.

If you do not have a letter from your GP or hospital specialist inviting you for a 3rd dose, you must bring either:

  • a hospital letter that describes the condition or treatment that caused you to have a severely weakened immune system at the time of your 1st or 2nd dose
  • a prescription or a medicine box with your name and the date showing when the medicine was prescribed - this must show that you had a severely weakened immune system at the time of your 1st or 2nd dose
  • A clinician at the site will check to make sure that you’re eligible for a 3rd dose.

If you think you’re eligible for a 3rd dose but you do not have a suitable letter, prescription or medicine box, please contact your GP or hospital specialist.

If you're booking a booster (4th dose) all of these must apply:

  • you have a letter from a GP or hospital specialist inviting you to book a 3rd dose or booster (4th dose) for people with a severely weakened immune system
  • you're aged 16 years old or over
  • it's been 2 months (61 days) since your previous dose - you'll be shown appointments from 3 months (91 days) after your previous dose
  • You'll need to bring the letter with you to your appointment.

A clinician at the site will check to make sure that you're eligible for a booster (4th dose).

If you think you're eligible for a booster (4th dose) but you do not have a suitable letter, please contact your GP or hospital specialist.

Learn more: 

MDS Patient Support

Covid Vaccines and Treatments for MDS Patients – 21st February 2022 status - Postal Letter to Members

Please read this clear summary and guidelines for MDS patients. Print it and share it with your GP if necessary.

Download PDF

MDS Patient Support

Please know we are continuing to communicate with NHSE to improve the situation on both vaccination and treatment

Which medical evidence can be used to confirm your eligibility for the 3rd and 4th doses? (Excerpt from the NHS document)

"If you are eligible and you do not have a referral letter from your GP or hospital consultant, you can still opt for a walk-in vaccination appointment, but you will need to present relevant medical documentation confirming your condition and have an assessment on site by a qualified healthcare professional.
It is important to be aware that not every walk-in site is able to offer vaccination for people who are severely immunosuppressed, so please use our online walk-in site finder to make sure you choose the right site for you.
Examples of medical evidence that can be used to confirm your eligibility includes, but is not limited to:
• A hospital letter describing your condition at the time of your 1st and/or 2nd dose.
• Evidence of prescribed medication at the time of your 1st/2nd dose – either in a hospital letter that describes the medication being prescribed, a prescription copy or a medication box with your name and the date on it."


Letter to Members with Updated Advice on Covid-19 for MDS Patients

Summary of latest advice on COVID protection – Updated on February, 2022

Dear MDS patients,

At the end of February we sent out a postal letter to all patients without internet access.

The postal letter included the latest Covid instructions.

We include these instructions here so that you can read them carefully and follow them to increase your protection.

We are aware that not all MDS patients have received this information from the NHS. Please show it to your GP if necessary.

We keep working to resolve issues with the NHS to ensure all patients receive all necessary official letters.

Best wishes,

Caroline Mc Govern – Office Manager

Chaudian Morgan – Membership Officer

Sophie Wintrich – CEO

Covid Vaccines and Covid Treatments – 21st February 2022 status

Some MDS patients have had problems getting access to their fourth dose of the covid vaccine and may not have been made aware of the four new COVID treatments available to MDS patients, both of which they are entitled to. This is the result of the NHS Digital having omitted to include several types of blood cancers, and due to the overwhelming pressure of work at many GP surgeries. Some of you will have received all the relevant information, but for those who have not, here are some tips put together by fellow MDS patients who had missed out on information from NHS centrally, or their GP.

All MDS patients are urged to ensure that they receive their 4th vaccine, and that they are aware of the priority COVID treatments and how to obtain them if they develop COVID symptoms.

4th Dose of COVID Vaccine

MDS patients should receive a 1st, 2nd, and 3rd 'Primary' dose, and then a 4th dose (the 'Booster') at least 91 days after the 3rd Primary dose. Experience of many of our members has found that, at some GP surgeries, MDS patients have had their 3rd dose recorded as a 'booster' in error - which has then led to them not being invited back for their 4th dose (their real 'booster').

If that has happened to you:

  • Contact your GP surgery and ask for your 4th dose of the covid vaccine.
  • If necessary, remind your GP surgery that an MDS diagnosis puts you in the highly vulnerable group (with MDS being a rare condition, the Admin Staff at GP surgeries can often not be aware of this).
  • You can also get your 4th dose at a Walk-In Centre, but you may need a letter from your consultant.
  • Contact your MDS clinical care team (via your specialist hospital nurse or Consultant’s office) if you haven’t already had a letter which states that you needed a 3rd Primary dose / 4th Booster dose.

 Access to Urgent Treatments Should You Catch Covid

All MDS patients are also entitled to be assessed to receive one of four different covid treatments, two of which are given intravenously on a day-visit to a local hospital, and two which are dispensed in tablet form.
These medicines are called Sotrovimab, Paxlovid, Remdesivir and Molnupiravir.

These drug treatments must be started within 5 days of symptoms starting – so speedy access is crucial.

Priority PCR Test Kits are available to MDS patients to have on 'stand-by' at home to help speed up the process. If you haven't already been sent one then you should telephone the NHS 119, see below.

Do this straightaway, and don’t wait until you develop symptoms, the idea is to have one on hand at home in case you need one. These priority PCR test kits are labelled differently to ordinary PCR test kits, so that when they are received at the laboratory and they are confirmed as positive for COVID, you are 'flagged' for priority access to the treatments through what is known as a CMDU (Covid Medicines Delivery Unit).

  • Dial 119 (be prepared to have to make up to 7 or 8 ‘option’ choices). You need to speak with someone about PCR tests, to obtain a ‘Priority PCR Test Kit.’ You may need to be gently persistent and ask to be put through to the Elective Care Team. They will be able to take your details and send you the Priority Kit.
  • If you develop covid symptoms use this Priority PCR Kit and send it off URGENTLY.
  • It is not absolutely necessary to use the Priority PCR Kit if you haven't received one. It is also now possible to use an LFT (Lateral Flow Test) but if you do, it is important that you register the result by phoning 119 (or if you are able, online at https://www.gov.uk/report-covid19-result ).

Because of the urgency required in receiving these treatments if you catch covid, it is also recommended that if you test positive on a Lateral Flow Test at home, or through a PCR test that you have sent away, you should also contact your hospital MDS care team as soon as possible to advise them, as they may also be able to arrange for you to receive one of the urgent treatments.

This 'belt & braces' approach is recommended, to reduce the risk of any delay in receiving one of the treatments. Remember that the COVID treatments must be started within 5 days of symptoms appearing.

Covid Vaccines and Treatments for MDS Patients – 21st February 2022 status - Postal Letter to Members

Please read this clear summary and guidelines for MDS patients. Print it and share it with your GP if necessary.

Download PDF


CCS-1477

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

CCS-1477

  1. SUB-TYPE OF MDS: All subtypes of MDS
  2. SEVERITY OF MDS: High Risk MDS and Acute myeloid leukaemia.
  3. NAME OF DRUG: CCS-1477 . CCS-1477 is a drug in oral form that blocks certain enzymes that are needed to encourage the expression of genes that drive cancer. It also causes the destruction of some proteins that are important in cancer cell development.
  4. Aims and benefits: This Phase I/IIa study investigates the safety, tolerability and activity of CCS-1477 in the body.
  5. Primary outcome: To identify adverse events related to the treatment.
  6. Secondary outcome: To determine the rate of response and duration of response to the treatment.

Read More


PDR001 and/or MBG453 in Combination with Decitabine or Azacitidine

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

PDR001 and/or MBG453 in Combination with Decitabine or Azacitidine

  1. SUB-TYPE OF MDS: All patients with MDS (but see basic exclusion criteria below)
  2. SEVERITY OF MDS: Intermediate or High Risk MDS and Acute myeloid leukaemia.
  3. NAME OF DRUG: PDR001, MBG453. PDR001 is an antibody that makes cancer cells recognizable to the immune system thus resulting in reduction of tumour growth and size. MBG453 is an antibody that blocks a marker on leukaemia cells (TIM-3) thus making them more vulnerable to the effect of drugs used in leukaemia treatment.
  4. Aims and benefits: This Phase I study investigates different doses of the drugs PDR001 and/or MBG453 to determine the dose which is safe, well tolerated and effective. It investigates the drugs when used on their own as well as in combination with each other and in combination with Decitabine or Azacitidine.
  5. Primary outcome: To identify toxicities that occur due to dosage of the study drugs. To determine the safety of the study drugs when used on their own and in combination.

Read More


Verona

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

Venetoclax

  1. SUB-TYPE OF MDS: All patients with MDS (but see basic exclusion criteria below)
  2. SEVERITY OF MDS: Revised International Prognostic Scoring System (IPSS-R) score > 3 (intermediate, high or very high).
  3. NAME OF DRUG: Venetoclax. Venetoclax is an inhibitor of BCL-2, thus promoting programmed death of tumour cells.
  4. Aims and benefits: This is a randomised double-blind, Phase 3 study aimed at determining the safety and effectiveness of Venetoclax when used in combination with Azacitidine in newly diagnosed patients with Higher risk Myelodysplastic syndrome.
  5. Primary outcome: To determine complete response and overall survival.
  6. Secondary outcome: To determine the rate of achieving transfusion independence.

Read More


KRT-232

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

KRT-232

  1. SUB-TYPE OF MDS: Patients with MDS or CMML who have relapsed from or are refractory to previous therapy
  2. SEVERITY OF MDS: Intermediate, High or Very High Risk
  3. NAME OF DRUG: KRT-232
  4. Aims and benefits: This Phase Ib/2 study that investigates the safety and effectiveness of KRT-232 when taken alone and in combination with Low-dose Cytarabine or Decitabine in patients with acute myeloid leukaemia (AML) including AML secondary to myeloproliferative disorders.
  5. Primary outcome: To determine the recommended dose of KRT-232 as well as its safety and tolerability. KRT-232 targets MDM2 thus preventing it from inhibiting p53. P53 has a role in arresting the tumour cell cycle and in promoting programmed death of tumour cells.
  6. Secondary outcome: To determine response rates.

Read More


Free donations by shopping